JPJong Sung Park

Jong Sung Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jong Sung Park has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subcutaneous Defibrillator for Primary Prevention in Chronic Kidney Disease Stage 3–5: The Single‐Arm STEADIED Study

    by Tae‐Wan Chung, Tae‐Hoon Kim, Boyoung Joung, Seung‐Jung Park, Eue‐Keun Choi, Myung‐Hwan Bae, Jong Sung Park, Il‐Young Oh, Min‐Soo Cho, Jong‐Sung Park, et al.

    Background: Prospective data on the subcutaneous implantable cardioverter‐defibrillator (S‐ICD) in chronic kidney disease (CKD) are lacking. We estimated the rate of appropriate ICD therapy with the S‐ICD in CKD stage 3–5 with left ventricular ejection fraction (LVEF) ≤ 35%. Methods: In this single‐arm exploratory study, adults with CKD stage 3–5 and a guideline‐based primary‐prevention indication received an EMBLEM MRI S‐ICD at eight Korean centers. The primary endpoint, appropriate ICD therapy, was hypothesized at 18% versus a historical rate of 7.8% ( α = 0.05, 80% power, planned N = 77; exact binomial test). Results: The study was terminated early after 39 patients (51% of target; achieved power ≈61%). Mean LVEF was 27.8% and median eGFR 11.7 mL/min/1.73 m 2 ; 71.8% had CKD stage 5 and 69.2% were on hemodialysis. Over a median follow‐up of 361 days, appropriate ICD therapy occurred in 2 patients (5.1%; 95% CI, 1.4–16.9), significantly below the hypothesized 18% ( p = 0.036). Inappropriate shocks occurred in 5 patients (12.8%; 95% CI, 5.6–26.7; 8 shocks), a proportion 2.5 times that of appropriate therapy, from external electromagnetic interference (2 patients), multiple counting after automatic SMART Pass deactivation (2), and supraventricular misclassification (1). Three deaths (7.7%) occurred, none device‐related or documented as arrhythmic (one undetermined); all hospitalizations were for heart failure, and no systemic device infection occurred. Conclusions: In this exploratory single‐arm study, appropriate ICD therapy was infrequent and exceeded by inappropriate shocks, while non‐arrhythmic competing mortality dominated the clinical course. These hypothesis‐generating findings support cautious patient selection, verification of filter status during follow‐up, and larger comparative studies. Trial Registration: Clinical Research Information Service (CRIS), Republic of Korea; identifier KCT0005596

  • Open Access

    Long‐Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS

    by Youngjoon Kwon, Namkyun Kim, Do‐Hoon Kim, Byungwon Kim, Jong Sung Park, Yoon Jung Park, Bo Eun Park, Hong Nyun Kim, Jang Hoon Lee, Dong Heon Yang, et al.

    Background: Intravascular ultrasound (IVUS)‐guided percutaneous coronary intervention improves patient outcomes, yet the impact of a center's IVUS experience on long‐term outcomes remains unclear. We evaluated whether the prognostic association of IVUS‐guided percutaneous coronary intervention in patients with acute myocardial infarction differs based on a center's level of IVUS use. Methods: We retrospectively analyzed 9752 patients with acute myocardial infarction treated with second‐generation drug‐eluting stents from the KAMIR‐NIH (Korean Acute Myocardial Infarction Registry–National Institutes of Health). The primary outcome was 3‐year major adverse cardiovascular events, defined as a composite of all‐cause death, myocardial infarction, and coronary revascularization. The secondary outcome was target‐lesion failure, defined as a composite of cardiac death, target‐vessel myocardial infarction, and ischemia‐driven target lesion revascularization. Centers were classified into higher‐ or lower‐IVUS‐use groups on the basis of median institutional usage (10.3%). Results: In higher‐use centers, IVUS‐guided percutaneous coronary intervention was associated with lower rates of major adverse cardiovascular events (15.3% versus 18.5%, P =0.016) and target‐lesion failure (6.3% versus 8.3%, P =0.039) in propensity score–matched populations. Multivariate Cox analysis confirmed lower risks of major adverse cardiovascular events (hazard ratio [HR], 0.80 [95% CI, 0.69–0.93]; P =0.003) and target‐lesion failure (HR, 0.75 [95% CI, 0.59–0.93]; P =0.01). Conversely, in lower‐use centers, IVUS guidance was not associated with significant differences in major adverse cardiovascular events (15.7% versus 18.6%, P =0.422) or target‐lesion failure (8.9% versus 10.4%, P =0.644). Conclusions: The association of IVUS‐guided percutaneous coronary intervention with lower adverse event rates was more apparent and statistically demonstrable in centers with higher IVUS use. These findings suggest that institutional experience may amplify the observable impact of IVUS guidance, underscoring the potential value of standardized IVUS implementation in acute myocardial infarction management.

  • Open Access

    Differentiating Left Atrial Pressure Responses in Paroxysmal and Persistent Atrial Fibrillation: Implications for Diagnosing Heart Failure With Preserved Ejection Fraction and Managing Atrial Fibrillation

    by Jong Sung Park, Iksung Cho, Daehoon Kim, Moon‐Hyun Kim, Je‐Wook Park, Hee Tae Yu, Tae‐Hoon Kim, Jae‐Sun Uhm, Boyoung Joung, Moon‐Hyoung Lee, et al.

    Background: Increased left atrial pressure (LAP) contributes to dyspnea and heart failure with preserved ejection fraction in patients with atrial fibrillation (AF). The purpose of this study was to investigate the differences in baseline LAP and LAP response to rapid pacing between paroxysmal and persistent AF. Methods and Results: This observational study prospectively enrolled 1369 participants who underwent AF catheter ablation, excluding those with reduced left ventricular ejection fraction. H 2 FPEF score was calculated by echocardiography and baseline characteristics. Patients underwent LAP measurements during AF, sinus rhythm, and heart rates of 90, 100, 110, and 120 beats per minute (bpm), induced by right atrial pacing and isoproterenol. The baseline LAP‐peak in the persistent AF group consistently exceeded that in the paroxysmal AF (PAF) group across each H 2 FPEF score subgroup (all P P P =0.056) because the LAP‐peak significantly increased with heart rate in the group with PAF. Conclusions: Patients with PAF exhibited lower baseline LAP with greater increases during rapid pacing compared with individuals with persistent AF, indicating a need to revise the H 2 FPEF score for distinguishing PAF from persistent AF and emphasizing the importance of rate and rhythm control in PAF for symptom control. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02138695.


  • Open Access

    Diagnostic Value of a Wearable Continuous Electrocardiogram Monitoring Device (AT-Patch) for New-Onset Atrial Fibrillation in High-Risk Patients: Prospective Cohort Study

    by Ju-Seung Kwun, Jang Hoon Lee, Bo Eun Park, Jong Sung Park, Hyeon Jeong Kim, Sun-Hwa Kim, Ki-Hyun Jeon, Hyoung-Won Cho, Si-Hyuck Kang, Wonjae Lee, et al.

    Background: While conventional electrocardiogram monitoring devices are useful for detecting atrial fibrillation, they have considerable drawbacks, including a short monitoring duration and invasive device implantation. The use of patch-type devices circumvents these drawbacks and has shown comparable diagnostic capability for the early detection of atrial fibrillation. Objective: We aimed to determine whether a patch-type device (AT-Patch) applied to patients with a high risk of new-onset atrial fibrillation defined by the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex scale (CHA2DS2-VASc) score had increased detection rates. Methods: In this nonrandomized multicenter prospective cohort study, we enrolled 320 adults aged ≥19 years who had never experienced atrial fibrillation and whose CHA2DS2-VASc score was ≥2. The AT-Patch was attached to each individual for 11 days, and the data were analyzed for arrhythmic events by 2 independent cardiologists. Results: Atrial fibrillation was detected by the AT-Patch in 3.4% (11/320) of patients, as diagnosed by both cardiologists. Interestingly, when participants with or without atrial fibrillation were compared, a previous history of heart failure was significantly more common in the atrial fibrillation group (n=4/11, 36.4% vs n=16/309, 5.2%, respectively; P=.003). When a CHA2DS2-VASc score ≥4 was combined with previous heart failure, the detection rate was significantly increased to 24.4%. Comparison of the recorded electrocardiogram data revealed that supraventricular and ventricular ectopic rhythms were significantly more frequent in the new-onset atrial fibrillation group compared with nonatrial fibrillation group (3.4% vs 0.4%; P=.001 and 5.2% vs 1.2%; P<.001), respectively. Conclusions: This study detected a moderate number of new-onset atrial fibrillations in high-risk patients using the AT-Patch device. Further studies will aim to investigate the value of early detection of atrial fibrillation, particularly in patients with heart failure as a means of reducing adverse clinical outcomes of atrial fibrillation. Trial Registration: ClinicalTrials.gov NCT04857268; https://classic.clinicaltrials.gov/ct2/show/NCT04857268


  • Open Access

    Diagnostic Value of a Wearable Continuous Electrocardiogram Monitoring Device (AT-Patch) for New-Onset Atrial Fibrillation in High-Risk Patients: Prospective Cohort Study (Preprint)

    by Ju-Seung Kwun, Jang Hoon Lee, Bo Eun Park, Jong Sung Park, Hyeon Jeong Kim, Sun-Hwa Kim, Ki-Hyun Jeon, Hyoung-Won Cho, Si-Hyuck Kang, Wonjae Lee, et al.

    BACKGROUND While conventional electrocardiogram monitoring devices are useful for detecting atrial fibrillation, they have considerable drawbacks, including a short monitoring duration and invasive device implantation. The use of patch-type devices circumvents these drawbacks and has shown comparable diagnostic capability for the early detection of atrial fibrillation. OBJECTIVE We aimed to determine whether a patch-type device (AT-Patch) applied to patients with a high risk of new-onset atrial fibrillation defined by the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex scale (CHA2DS2-VASc) score had increased detection rates. METHODS In this nonrandomized multicenter prospective cohort study, we enrolled 320 adults aged ≥19 years who had never experienced atrial fibrillation and whose CHA2DS2-VASc score was ≥2. The AT-Patch was attached to each individual for 11 days, and the data were analyzed for arrhythmic events by 2 independent cardiologists. RESULTS Atrial fibrillation was detected by the AT-Patch in 3.4% (11/320) of patients, as diagnosed by both cardiologists. Interestingly, when participants with or without atrial fibrillation were compared, a previous history of heart failure was significantly more common in the atrial fibrillation group (n=4/11, 36.4% vs n=16/309, 5.2%, respectively; P=.003). When a CHA2DS2-VASc score ≥4 was combined with previous heart failure, the detection rate was significantly increased to 24.4%. Comparison of the recorded electrocardiogram data revealed that supraventricular and ventricular ectopic rhythms were significantly more frequent in the new-onset atrial fibrillation group compared with nonatrial fibrillation group (3.4% vs 0.4%; P=.001 and 5.2% vs 1.2%; P<.001), respectively. CONCLUSIONS This study detected a moderate number of new-onset atrial fibrillations in high-risk patients using the AT-Patch device. Further studies will aim to investigate the value of early detection of atrial fibrillation, particularly in patients with heart failure as a means of reducing adverse clinical outcomes of atrial fibrillation. CLINICALTRIAL ClinicalTrials.gov NCT04857268; https://classic.clinicaltrials.gov/ct2/show/NCT04857268

  • Open Access

    Predictors of stroke or systemic embolism in patients with non‐valvular atrial fibrillation with CHA2DS2‐VASc score of 0

    by Hyohun Choi, Myung Hwan Bae, Yoon Jung Park, Hyuk Kyoon Park, Eunkyu Lee, Myeong Seop Kim, Jong Sung Park, Hyeon Jeong Kim, Bo Eun Park, Hong Nyun Kim, et al.

    Background: Anticoagulant therapy has been important for stroke prevention in patients with atrial fibrillation (AF). However, it was not recommended due to its relatively higher risk of bleeding than its lower risk of stroke in patients with a CHA2DS2‐VASc score of 0.Hypothesis: This study aimed to evaluate the predictors of stroke in AF patients with very low risk of stroke.Methods: Between 1990 and 2020, 542 patients with non‐valvular AF (NVAF) with a CHA2DS2‐VASc score of 0 followed up for at least 6 months were enrolled. Patients with only being woman as a risk factor were included as a CHA2DS2‐VASc score of 0 in this study. The primary outcome was stroke or systemic embolism.Results: The primary outcome rate was 0.78%/year. In Cox hazard model, age of ≥50 years at diagnosis (hazard ratio [HR] 6.710, 95% confidence interval [CI] 1.811–24.860, p = .004), LVEDD of ≥46 mm (HR 4.513, 95% CI 1.038–19.626, p = .045), and non‐paroxysmal AF (HR 5.575, 95% CI 1.621–19.175, p = .006) were identified as independent predictors of stroke or systemic embolism. Patients with all three independent predictors had a higher risk of stroke or systemic embolism (4.21%/year), whereas those without did not have a stroke or systemic embolism.Conclusion: The annual stroke or systemic embolism rate in NVAF patients with CHA2DS2‐VASc score of 0 was 0.78%/year, and age at AF diagnosis, LVEDD, and non‐paroxysmal AF were independent predictors of stroke or systemic embolism in patients considered to have a very low risk of stroke.


  • Open Access

    Impact of Positron Emission Tomography Viability Imaging: Guided Revascularizations on Clinical Outcomes in Patients With Myocardial Scar on Single-Photon Emission Computed Tomography Scans

    by Jong Sung Park, Jang Hoon Lee, Chae Moon Hong, Bo Eun Park, Yoon Jung Park, Hong Nyun Kim, Namkyun Kim, Se Yong Jang, Myung Hwan Bae, Dong Heon Yang, et al.

    Park JS, et al. J Korean Med Sci. 2023 Nov;38:e399. https://doi.org/10.3346/jkms.2023.38.e399